Truist Reiterates Buy Rating on Sangamo BioSciences (SGMO), Removes PT

Truist Securities analyst Nicole Germino reiterated a Buy rating on Sangamo BioSciences (NASDAQ: SGMO).

The analyst commented: "Potential BLA filing in 2H25 but cash overhang remains; SGMO continues to advance internal programs for chronic neuropathic pain and prion disease with initial data expected in 4Q26; however, near-term cash remains an overhang. With two capsid delivery agreements, we see Big Pharma interest in SGMO's platform and SGMO is in advanced discussions with a third potential partner for STAC-BBB. We await clarity on a potential partner for their Fabry disease program, which could meaningfully extend their cash runway beyond 2026. We update our model for 4Q24 and Fabry ramp. Given the recent volatility and low share price, we are removing our PT on SGMO and maintain our Buy rating."

For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.

Shares of Sangamo BioSciences closed at $0.85 yesterday.

You May Also Be Interested In

• Bullish (BLSH) PT Raised to $30 at Compass Point
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward